Document Detail

Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7.
MedLine Citation:
PMID:  9274718     Owner:  NLM     Status:  MEDLINE    
We have completed a phase I study to test feasibility and toxicity of immunotherapy of hepatic metastases from colorectal carcinoma by direct gene transfer of HLA-B7, a MHC class I gene. Eligible patients were HLA-B7 negative, immunocompetent by PHA lymphocyte stimulation and had at least two measurable hepatic lesions on CT scan for measurement of response of the injected lesion, as well as evaluation of possible distant response. Under ultrasonographic guidance the hepatic lesions were injected with Allovectin-7, a liposomal vector containing the combination of the HLA-B7 gene with beta 2-microglobulin formulated with the lipid DMRIE-DOPE. Eligible patients were injected on two schedules. On the first schedule patients received an injection on day 1 and the injected lesion was biopsied to determine transfection every 2 weeks for 8 weeks. Doses were escalated from 10 micrograms to 50 micrograms to 250 micrograms with three patients treated at each level. The second schedule included multiple injections of 10 micrograms. Three patients received injections on days 1 and 15. Three patients received injections on days 1, 15 and 29. A total of 15 patients have completed treatment. The plasmid DNA was detected in 14 of 15 patients (93%) by PCR. In five of 15 patients (33%) mRNA was also detected. The HLA-B7 protein was detected in five of eight patients (63%) by immunohistochemistry and in seven of 14 patients (50%) tested by fluorescence activated cell sorting (FACS) analysis. There has been no serious toxicity directly attributable to allovectin-7. Our results suggest that liposomal gene transfer by direct injection is feasible and non-toxic. Further studies will be necessary in order to establish the therapeutic efficacy.
J Rubin; E Galanis; H C Pitot; R L Richardson; P A Burch; J W Charboneau; C C Reading; B D Lewis; S Stahl; E T Akporiaye; D T Harris
Related Documents :
554668 - The treatment of sarcoidosis by levamisole.
7272208 - Response of alopecia areata to dncb: influence of auto-antibodies and route of sensitiz...
8637398 - A sustained increase in beta-adrenoceptors during long-term therapy with metoprolol and...
3165688 - Erythremic [corrected] myelosis in chronic lymphocytic leukemia.
24320758 - Differing effects of liraglutide on gastric emptying in japanese patients with type 2 d...
6742078 - Biofeedback therapy of essential blepharospasm.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Gene therapy     Volume:  4     ISSN:  0969-7128     ISO Abbreviation:  Gene Ther.     Publication Date:  1997 May 
Date Detail:
Created Date:  1997-09-19     Completed Date:  1997-09-19     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9421525     Medline TA:  Gene Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  419-25     Citation Subset:  IM    
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Colorectal Neoplasms*
Flow Cytometry
Gene Expression
Gene Therapy / methods*
Gene Transfer Techniques*
Genetic Vectors
HLA-B7 Antigen / genetics*
Immunotherapy / methods*
Liver Neoplasms / secondary*,  therapy*
Middle Aged
Grant Support
Reg. No./Substance:
0/HLA-B7 Antigen; 0/Liposomes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery.
Next Document:  Kidney-targeted liposome-mediated gene transfer in mice.